New York, July 11, 2026 – 3M Company (NYSE:MMM) saw its market value increase by approximately $1.1 billion on Friday, with shares rising $2.18, or 1.4%, to close at $157.52. The gain came even as New York State filed another lawsuit targeting 3M and other companies over per- and polyfluoroalkyl substances (PFAS), commonly known as “forever chemicals.” Despite the uptick, the stock ended the week down 1.8%, with trading volume at 1.94 million shares, just 51% of the 65-day average. U.S. markets were closed for the weekend, and the bounce appeared muted.
Analyst Sentiment Improves
Behind the scenes, analysts have been quietly raising their profit targets for 3M. The consensus estimate for 2026 adjusted earnings per share (EPS), which excludes certain special items, now stands at $8.73, up from $8.66 three months ago. This is $0.03 above the upper end of 3M’s own guidance range of $8.50 to $8.70. For the second quarter, the adjusted EPS consensus is $2.25, two cents higher than a month earlier, tightening the bar for an in-line report.
Key Financial Metrics
- Second-quarter adjusted EPS consensus: $2.25 (vs. $2.23 a month ago)
- 2026 adjusted EPS consensus: $8.73 (vs. $8.66 three months ago)
- 3M’s 2026 adjusted EPS outlook: $8.50–$8.70
- Price divided by guidance midpoint: 18.3 times ($157.52 / $8.60)
- Median analyst price target: $178 (13% above Friday’s close)
Upcoming Earnings and Legal Challenges
The tension builds just 10 days before 3M’s Q2 conference call, scheduled for July 21 at 8 a.m. Central. Wolfe Research analyst Nigel Coe reiterated a Buy rating on July 9, maintaining a $189 price target, roughly 20% above Friday’s close. However, 3M must deliver strong earnings to justify the optimism. The company lagged the S&P 500 by about three percentage points for the week, with other industrials also declining. Honeywell International (NASDAQ:HON) fell 1.5%, Illinois Tool Works (NYSE:ITW) slipped 1.4%, and DuPont de Nemours (NYSE:DD), a co-defendant in the New York lawsuit, dropped 3.7%.
PFAS Lawsuit Details
New York’s complaint seeks cleanup costs, consumer warnings, damages, restitution, and civil penalties, but does not specify a dollar amount. The lawsuit alleges that 3M, DuPont, and others knowingly sold PFAS, which do not break down in the environment or the human body. The companies did not respond to requests for comment. The legal overhang adds uncertainty to 3M’s outlook.
Operational Performance and Cash Position
3M entered the quarter in better operational shape. First-quarter adjusted EPS rose 14% to $2.14, and adjusted operating margin improved by 0.30 percentage point. However, CFO Anurag Maheshwari noted that first-half earnings per share are expected to be higher than the second half, making the profit split a key focus. Cash, equivalents, and marketable securities fell to $4.2 billion at March 31 from $5.9 billion at year-end, driven by $2 billion in buybacks, $400 million in dividends, and $300 million in legal and PFAS-related costs, partially offset by $300 million in insurance recoveries. The company still has $2.7 billion remaining on its buyback program.
Economic Data Ahead
Investors face four key economic reports before 3M’s earnings: June’s Consumer Price Index on Tuesday, July 14; Producer Price Index on Wednesday; retail sales on Thursday; and industrial production on Friday. These data points will test 3M’s views on input cost pressures and demand for industrial goods.
Risks and Outlook
The setup remains shaky. Any new legal expenses, higher producer prices, or disappointing factory numbers could turn the $8.73 consensus target into a downgrade risk. If earnings miss the $2.25 quarterly estimate or if management signals a skew toward first-half profits, Friday’s thin bounce could be vulnerable. The lawsuit’s unspecified damages make it difficult to quantify the hit, but the risk is real.
On July 21, investors will focus on adjusted organic sales growth, margin trends, and share repurchase activity amid ongoing legal payouts. A beat and an outlook hike would clear the bar, while a beat with unchanged guidance might not satisfy the market.
